trial

Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia

NCTId NCT02237235
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 60 (actual)
Sponsored by Northwestern University
Primary completion 2017-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
60 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2014-08
Primary completion
2017-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
MMFS-202-302

Sponsors

Northwestern UniversityLead Sponsor
Neurocentria, Inc.Collaborator
Brain & Behavior Research FoundationCollaborator

Investigators

1
Herbert Y Meltzer, MDPrincipal Investigator

Sites

1 total
Chicago, United States

Linked catalysts

1
Effect of MMFS-202-302 on Cognitive Enhancement in Schizophrenia — primary completion2017-08

Facts & assertions

4 sourced
Enrollment
60
Phase
PHASE2
Primary Completion Date
2017-08
Status
COMPLETED
relationships
The graph out of here
drug
MMFS-202-302
drug
lead_sponsor
Northwestern University
company
collaborator
Neurocentria, Inc.
company
Brain & Behavior Research Foundation
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Herbert Y Meltzer, MD
person